Common Reasons for Deficiency Letters in Thailand Medical Device Registration

Answer: The most common reasons for deficiency letters or requests for additional information in Thailand medical device registration are incorrect product classification or pathway selection, inadequate adaptation of existing NMPA, CE, or FDA documents to Thai FDA requirements, inconsistent evidence across technical files and test reports, insufficient model or specification coverage, labeling and IFU mismatches, unclear authorization and local representative responsibilities, incomplete QMS evidence, and weak post-market maintenance planning. Registration usually requires confirming the product classification and applicable pathway first, then preparing technical files, labels and instructions for use, QMS certificates, authorization documents, and local representative information. Existing NMPA dossiers may serve as a foundation, but they normally need language, format, labeling, and evidence-chain adaptation for the Thai FDA.

Published: July 10, 2026, 12:44

Updated: July 10, 2026, 12:44

Key Summary

Thailand medical device registration typically begins with confirming product classification and the applicable route, followed by preparing technical files, labels and instructions for use, QMS evidence, authorization documents, and local representative information. Existing NMPA documents can be used as a basis, but they usually need to be adapted to Thai FDA requirements for language, format, labeling, and evidence chain.

For Chinese medical device companies, a prudent approach is to perform a product classification and documentation gap assessment first, then decide whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused.

Thailand registration often affects technical files, authorized representation, importer cooperation, label language, QMS evidence, and subsequent change maintenance. If a company proceeds only by asking “which documents must be submitted,” it is more likely to encounter deficiency letters or rework related to model coverage, evidence-chain consistency, labeling claims, and certificate control.

AIMEILI recommends planning this issue within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than recreating dossiers country by country.

Companies should also make project-based judgments based on the latest requirements of the target regulatory authority, existing technical file basis, product risk level, and launch plan, instead of mechanically preparing documents from a checklist.

Source note: Compiled from AIMEILI regulatory practice questions, the medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target regulatory authority and the product’s documentation basis.

Applicable Scenarios and Core Questions

Companies searching for “common reasons for deficiency letters in Thailand medical device registration” usually want to know whether existing documents can support a Thai submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America, answering only one country’s process is not enough. A more valuable approach is to first develop reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence, and labels/IFUs, and then localize them according to each country’s regulatory requirements.

Registration Decision Logic

Companies should first confirm the product’s intended use, mechanism of action, use environment, body-contact method, duration of use, sterility, active status, and whether it contains software or IVD attributes, and then determine the risk class and submission pathway. If the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For a Thailand project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages import and post-market incidents, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, market control can be affected later.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFUs, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. IFU claims, model coverage in test reports, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support one another. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company uploaded many files.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without reorganizing the evidence according to the Thai pathway.
• Too many models or specifications, but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibility, certificate control, and post-market maintenance duties.
• Inconsistency among labels, IFUs, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risks.
• Failure to plan multi-country document reuse in advance, causing repeated preparation for each country and increasing cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm their documentation basis, so that critical evidence gaps are not discovered only after submission.

• Organize the target product list, model/specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation, and English IFUs.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Build a target-country gap assessment table identifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not view Thailand registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more conducive to later changes and renewals than preparing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, evidence-chain consistency; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even a large document package may still lead to repeated deficiency responses, agent communication, and post-market maintenance issues.

Common Follow-up Questions

Can domestic Chinese documents be used directly for Thailand registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustment, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, QMS documents are not isolated certificates. Regulators often examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model/specifications, or IFU version is inconsistent with test reports, the authority may request additional explanation even if the company has prepared many documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model/specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and QMS certificate item by item. Although this appears basic, it can significantly reduce the probability of deficiency letters, especially for projects involving multiple GHWP member states or multiple product families submitted at the same time.

Localization Conversion and Agent Responsibilities

Thailand registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for document submission or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate isolated dossier.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining approval but neglect post-market maintenance; later, when manufacturing address changes, model expansion, IFU updates, or agent replacement occur, the certificate and market sales can become disconnected.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify target market priorities, then build a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but also helping the company develop replicable overseas compliance capabilities and reduce the cost of starting from zero each time it enters a new market.

Further Reading

• Previous: Why Is the Thailand Medical Device Registration Cycle Extended?
• Next: How Is Post-Market Surveillance Conducted for Thailand Medical Device Registration?
• Recommended: How Should Malaysia Medical Device Registration Documents Be Prepared?
• Recommended: How Should Product Classification Be Determined for Malaysia Medical Device Registration?
• Recommended: How Should Technical Files Be Organized for Malaysia Medical Device Registration?
• Recommended: How Should Labels and IFUs Be Localized for Malaysia Medical Device Registration?
• Recommended: How Should Clinical Evaluation Documents Be Prepared for Malaysia Medical Device Registration?
• Recommended: Can Test Reports Be Reused for Malaysia Medical Device Registration?
• Back to FAQ Center
• News and Information
• Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Applicability boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country’s regulatory authority, testing conclusions, or legal advice.